MICROSTRUCTURAL ORGANIZATION OF PERIODONTIUM UNDER CONDITIONS OF COMPLEX CORRECTION AGAINST THE BACKGROUND OF EXPERIMENTAL TEN-WEEK OPIOID EXPOSURE
Keywords:periodontal tissues, rats, opioid, correction, microscopic examinations.
In order to develop an adequate scheme of drug correction of periodontal tissue damage on the background of long-term action of the opioid analgesic nalbuphine, experimental studies were performed using the drugs pentoxifylline and ceftriaxone. The study was performed on male rats (24), which were divided into 3 groups. And the group is a control group. Group II – administration to rats of opioid analgesic in increasing doses for 10 weeks, where the initial dose was – 0.212 mg / kg, 9-10 weeks – 0.283 mg / kg. Group III – administration of pentoxifylline (7-10 weeks) and ceftriaxone (9-10 weeks) at a dosage of 2.86 mg against a 10-week opioid effect (from 0.212 to 0.283 mg / kg). For histological examinations, fragments of the dental segment of rats were collected using complex decalcification of the hard tissues of the dental organ. Microscopic studies in animals at 10 weeks of opioid action indicated pronounced inflammatory-dystrophic changes in periodontal tissues, which were manifested by necrotic changes in the mucous membrane of the gums, dystrophic periodontal damage and vascular disorders. Drug correction with pentoxifylline and ceftriaxone on the background of ten weeks of opioid action led to a protective effect on the microstructural organization of periodontal tissues of rats. Although complete restoration of periodontal structures in comparison with the control did not occur, however, the use of etiopathogenetic treatment contributed to a certain stabilization of the inflammatory process. The results showed that the use of pentoxifylline and ceftriaxone prevented the generalized progression of dystrophic changes in the periodontium with long-term opioid action, compared with the detected pathological changes in periodontal tissues in animals under ten weeks of opioid administration without corrective action.
Slat S, Yaganti A, Thomas J, Helminski D, Heisler M, Bohnert A, Lagisetty P. Opioid Policy and Chronic Pain Treatment Access Experiences: A Multi-Stakeholder Qualitative Analysis and Conceptual Model. Journal of Pain Research. 2021; 14:. 1161–1169. DOI: 10.2147/JPR.S282228.
Davis MP, Fernandez C, Regel S, McPherson ML. Does nalbuphine have a niche in managing pain? Journal of Opioid Management 2018; 14(2):143-151. DOI: 10.5055/jom.2018.0441
Béliveau A, Castilloux AM, Tannenbaum C, Vincent P, de Moura CS, Bernatsky S, Moride Y. Predictors of long-term use of prescription opioids in the community-dwelling population of adults without a cancer diagnosis: a retrospective cohort study. CMAJ Open. 2021;;9(1):E96-E106. doi: 10.9778/cmajo.20200076.
Cohen B, Ruth LJ, Preuss CV. Opioid Analgesics. 2021 Oct 18. In: Stat-Pearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. PMID: 29083658.
Arora PC, Ragi KGS, Arora A, Gupta A. Oral Health Behavoir and Treatment Needs among Drug Addicts and Controls in Amristar District: A Case-controlled Study. Journal of Neurosciences in Rural Practice 2019; 10(02): 201-206. DOI: 10.4103/jnrp.jnrp_309_18
Azadfard M, Huecker MR, Leaming JM. Opioid Addiction. 2021 Aug 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 28846246.
Fik VB, Paltov EV, Kryvko YY. Morphofunctional peculiarities of the periodontal tissue under conditions of simulated eight-week opioid effect. Deutscher Wissenschaftscherold German Science Herald. 2018; 1:14-17. DOI:10.19221/201814
Paltov EV, Kovalyshyn OA, Fik VB, Kryvko YYa, Podoliuk MV, Holey-ko MV. Pathomorphological changes in rats retinal layers at the end of the twelfth week of experimental opioid influence. International Academy Journal Web of Scholar. 2019; 4(34):19-22. DOI:10.31435/rsglobal_wos/30042019/6444
Richardson MG, Raymond BL. Lack of Evidence for Ceiling Effect for Buprenorphine Analgesia in Humans. Anesth Analg. 2018;127(1):310-311. doi: 10.1213/ANE.0000000000003368. PMID: 29624528.
Furdychko AI, Ilchyshyn MP, Fedun IR, Barylyak AYa, Slaba OM, Khoroz LM. Periodontal status in patients with diseases of hepatobiliary system, patients with diseases of hepatobiliary system, burdened with to-bacco and drug addiction. Wiadomości Lekarskie. 2020; 3(LXXIII): 517-520. DOI: 10.36740/WLek202003121.
Hegazi F, Alhazmi H, Abdullah A, Alamer N, Nelson J, Aldosari M, etal. Prevalence of oral conditions among methamphetamine users: NHANES 2009-2014. J Public Health Dent. 2021;81(1):21-28. doi: 10.1111/jphd.12389
Hartnett KP, Jackson KA, Felsen C, McDonald R, Bardossy AC, Gokhale RH, Kracalik I, Lucas T, McGovern O, Van Beneden CA, Mendoza M, Bohm M, Brooks JT, Asher AK, Magill SS, Fiore A, Blog D, Dufort EM, See I, Dumyati G. Bacterial and Fungal Infections in Persons Who Inject Drugs - Western New York, 2017. MMWR Morb Mortal Wkly Rep. 2019;68(26):583-586. doi: 10.15585/mmwr.mm6826a2
Sun D, Ye T, Ren P, Yu S. Prevalence and etiology of oral diseases in drug-addicted populations: a systematic review. Int J Clin Exp Med 2018;11(7):6521-6531 www.ijcem.com /ISSN:1940-5901/IJCEM0075796
Annamaraju P, Baradhi KM. Pentoxifylline. 2021 Aug 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 32644522.